Comparative Efficacy of High-Dose Dexamethasone Versus Methylprednisolone in Coronavirus Disease 2019 (COVID-19)-Associated Acute Respiratory Distress Syndrome
暂无分享,去创建一个
R. Škrbić | Biljana Zlojutro | Milka Jandrić | T. Kovačević | Danica Momčičević | P. Kovačević | S. Dragić | Jovana Malić | Branka Cancarevic-Djajic | M. Z. Rizwan
[1] Zhiqiang Ma,et al. Comparison Between Drug-Coated Balloon and Stents in Large De Novo Coronary Artery Disease: A Systematic Review and Meta-Analysis of RCT Data. , 2024, Cardiovascular drugs and therapy.
[2] Lujun Qiao,et al. A systematic review and meta-analysis of glucocorticoids treatment in severe COVID-19: methylprednisolone versus dexamethasone , 2023, BMC Infectious Diseases.
[3] A. Perner,et al. Higher-dose dexamethasone for patients with COVID-19 and hypoxaemia? , 2023, The Lancet.
[4] M. Mehrpooya,et al. Comparison of the efficacy of equivalent doses of dexamethasone, methylprednisolone, and hydrocortisone for treatment of COVID-19-related acute respiratory distress syndrome: a prospective three-arm randomized clinical trial , 2023, Wiener Medizinische Wochenschrift.
[5] V. Djajić,et al. Boosting ICU capacity during the COVID-19 pandemic in the western Balkan region, The Republic of Srpska experience , 2023, Journal of public health research.
[6] M. Montico,et al. Prolonged higher dose methylprednisolone versus conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS) , 2022, European Respiratory Journal.
[7] Hongxing Dang,et al. Safety and efficacy of corticosteroids in ARDS patients: a systematic review and meta-analysis of RCT data , 2022, Respiratory Research.
[8] B. Brown,et al. Low-dose versus high-dose dexamethasone for hospitalized patients with COVID-19 pneumonia: A randomized clinical trial , 2022, PloS one.
[9] Jason C. Gallagher,et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] Azizullah Beran,et al. Methylprednisolone May Be Superior to Dexamethasone in COVID-19: A Meta-Analysis of Randomized Controlled Trials. , 2022, American journal of therapeutics.
[11] F. Kapadia,et al. Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia , 2022, Intensive Care Medicine.
[12] K. C. Morris,et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis , 2022, medRxiv.
[13] Lujun Qiao,et al. The roles of methylprednisolone treatment in patients with COVID-19: A systematic review and meta-analysis , 2022, Steroids.
[14] F. Pálizas,et al. High- Versus Low-Dose Dexamethasone for the Treatment of COVID-19-Related Acute Respiratory Distress Syndrome: A Multicenter, Randomized Open-Label Clinical Trial , 2021, Journal of intensive care medicine.
[15] F. Kapadia,et al. Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial. , 2021, JAMA.
[16] Zhen Wang,et al. Comparison of pulse‐dose and high‐dose corticosteroids with no corticosteroid treatment for COVID‐19 pneumonia in the intensive care unit , 2021, Journal of medical virology.
[17] Jinrong Fu,et al. The signal pathways and treatment of cytokine storm in COVID-19 , 2021, Signal Transduction and Targeted Therapy.
[18] Taher Entezari-Maleki,et al. Therapeutic Application of Corticosteroids in COVID‐19: A Focus on Optimum Dose and Duration of Therapy , 2021, Journal of clinical pharmacology.
[19] Henry Laniado,et al. Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia , 2021, PloS one.
[20] Steve B Jones,et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial , 2021, Lancet.
[21] A. Torres,et al. Corticosteroids for CAP, influenza and COVID-19: when, how and benefits or harm? , 2021, European Respiratory Review.
[22] Wei Yang,et al. A Comparison of Methylprednisolone and Dexamethasone in Intensive Care Patients With COVID-19 , 2021, medRxiv.
[23] M. Moghadami,et al. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial , 2021, BMC Infectious Diseases.
[24] O. Gajic,et al. Successful implementation of modern critical care in the low-resources country Bosnia and Herzegovina , 2021, Medizinische Klinik - Intensivmedizin und Notfallmedizin.
[25] A. Jonas,et al. Corticosteroids for COVID-19-Associated ARDS , 2020 .
[26] Thomas Jaki,et al. Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report , 2020, The New England journal of medicine.
[27] Xu Li,et al. Acute respiratory failure in COVID-19: is it “typical” ARDS? , 2020, Critical Care.
[28] A. Selva-O'Callaghan,et al. Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review , 2020, Autoimmunity Reviews.
[29] Reem A Mustafa,et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[30] Fengxiang Wei,et al. Epidemiology and Clinical Characteristics of COVID-19. , 2020, Archives of Iranian medicine.
[31] Yue Dong,et al. Impact of weekly case-based tele-education on quality of care in a limited resource medical intensive care unit , 2019, Critical Care.
[32] G. Van den Berghe,et al. Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017 , 2018, Intensive Care Medicine.
[33] G. Meduri,et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. , 1998, JAMA.
[34] P. Guest,et al. Acute Respiratory Distress Syndrome and COVID-19: A Scoping Review and Meta-analysis. , 2021, Advances in experimental medicine and biology.
[35] W. Lim,et al. Dexamethasone in Hospitalized Patients with Covid-19 , 2021 .
[36] Arthur S Slutsky,et al. Acute Respiratory Distress Syndrome The Berlin Definition , 2012 .